Monday, April 4, 2011

Impax challenges heartburn drug patents

Generic drug maker Impax Laboratories Inc. is challenging patents around the heartburn drug Dexilant.
Those patents on the delayed-release 30-milligram and 60-milligram version of Dexilant are held by Takeda Pharmaceutical Co., which filed a patent infringement suit Friday against Hayward-based Impax (NASDAQ: IPXL) in U.S. District Court for the Northern District of California.

No comments:

Post a Comment